Complexation between darunavir and β-Cyclodextrin. Experimental and theoretical studies

KOGAWA, A.C.; ZOPPI, A.; QUEVEDO, M.A.; LONGHI, M.R.; NUNES SALGADO, H.R.

World Journal of Pharmacy and Pharmaceutical Sciences

World Journal of Pharmacy and Pharmaceutical Sciences

Año: 2014 vol. 3 p. 298 - 298

2278-4357

arunavir (DRV) is a protease inhibitor used in the treatment of HIVinfection, which constitutes a keystone in the therapy of patientsinfected with this virus. Unfortunately, DRV has low solubility inwater and poor bioavailability, therefore it requires administration inrelatively high doses in order to exhibit therapeutic efficacy. Acommonly applied approach to increase the solubility of drugs is theformation of complexes with macromolecules, of which molecularencapsulation with β-cyclodextrin (βCD) constitutes an alternative forthe development of new pharmaceutical dosage forms. Therefore, itwas to evaluate by theoretical (molecular modelling) and experimental(spectroscopic) approaches the possibility of obtaining an inclusioncomplex between DRV and βCD. From the results obtained by thedocking procedures, we found three clusters of conformations for the DRV:β-CD complex, corresponding to conformations in which the ligand moieties were buried into the β-CD hyd